Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38
10 mars 2025 10h13 HE
|
Genmab A/S
Company Announcement Johnson & Johnson has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38 Genmab will not...
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
04 mars 2025 11h58 HE
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; March 4, 2025 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523,...
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
28 févr. 2025 16h04 HE
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; February 28, 2025 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation...
Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab
28 févr. 2025 16h00 HE
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; February 28, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 614,676 restricted stock units to members of management and...
Capital Increase in Genmab as a Result of Employee Warrant Exercise
25 févr. 2025 14h30 HE
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; February 25, 2025 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 10,058 shares as a consequence of the exercise of employee warrants. The...
EPKINLY® (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular Lymphoma
20 févr. 2025 08h00 HE
|
Genmab A/S
Media ReleaseCOPENHAGEN, Denmark; February 20, 2025 Approval based on results from two Phase 1/2 EPCORE® clinical trials, which demonstrated strong and durable efficacy in patients with relapsed or...
Genmab to Participate in a Fireside Chat at the 45th Annual TD Cowen Health Care Conference
19 févr. 2025 09h14 HE
|
Genmab A/S
Media ReleaseCOPENHAGEN, Denmark; February 19, 2025Genmab A/S (Nasdaq: GMAB) announced today that its Chief Financial Officer Anthony Pagano and Chief Development Officer Judith Klimovsky will...
Notice to Convene the Annual General Meeting of Genmab A/S
13 févr. 2025 06h00 HE
|
Genmab A/S
Company Announcement Genmab A/S to hold Annual General Meeting on Wednesday March 12, 2025 COPENHAGEN, Denmark; February 13, 2025 – Genmab A/S (Nasdaq: GMAB) summons the Annual General Meeting on...
Genmab Files Annual Report with the U.S. Securities and Exchange Commission
12 févr. 2025 13h14 HE
|
Genmab A/S
Media ReleaseCOPENHAGEN, Denmark; February 12, 2025 Genmab filed Form 20-F for the financial year 2024 with the U.S. SEC Genmab A/S (Nasdaq: GMAB) announced today that it has filed its Annual Report...
Genmab Publishes 2024 Annual Report
12 févr. 2025 11h01 HE
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; February 12, 2025 – Genmab A/S (Nasdaq: GMAB) announced today the publication of its Annual Report for 2024. Below is a summary of business progress in 2024,...